Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with takayasu's arteritis

Pil Ki Min, Sungha Park, Jae Hun Jung, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Won Heum Shim

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: To evaluate the feasibility and efficacy of endovascular therapy combined with immunosuppression for the treatment of arterial occlusive disease in patients with Takayasu's arteritis (TA). Methods: From January 1998 to June 2003, 25 patients (22 women; age 37.8±15.5 years) with TA were treated with angioplasty for symptomatic lesions or with a hemodynamically significant aortic narrowing. The patients with active disease, defined as an increase in inflammatory markers (e.g., erythrocyte sedimentation rate [ESR]), were treated with immunosuppressive agents before intervention. Angioplasty was performed after the ESR had been normalized. Results: In the 25 patients, 58 vascular territories (7 aortic, 9 carotid, 3 vertebral, 11 subclavian, 2 superior mesenteric, 18 renal, 4 iliac, and 4 coronary arteries) were treated with angioplasty only (19 lesions) or with stents (39 lesions). The mean ESR when the vascular lesions were initially diagnosed was 35.6±26.2 mm/h, which fell to 18.5±7.8 mm/h after immunosuppressive therapy. The endovascular procedure was performed successfully in 52 (90%) of 58 lesions. During the mean 23.7±18.4-month follow-up, 9 (17%) treated segments restenosed; 4 were treated with repeat angioplasty. The overall cumulative primary clinical success rate was 82%; secondary clinical success was 90%. Conclusions: Endovascular therapy for stenotic lesions in patients with TA is safe and effective when disease activity is strictly controlled with immunosuppressive treatment.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Endovascular Therapy
Volume12
Issue number1
DOIs
Publication statusPublished - 2005 Feb 1

Fingerprint

Takayasu Arteritis
Arterial Occlusive Diseases
Immunosuppressive Agents
Angioplasty
Blood Sedimentation
Blood Vessels
Therapeutics
Endovascular Procedures
Immunosuppression
Stents
Coronary Vessels
Kidney

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{05f1e97d7f18405baa3c67e7ad010f34,
title = "Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with takayasu's arteritis",
abstract = "Purpose: To evaluate the feasibility and efficacy of endovascular therapy combined with immunosuppression for the treatment of arterial occlusive disease in patients with Takayasu's arteritis (TA). Methods: From January 1998 to June 2003, 25 patients (22 women; age 37.8±15.5 years) with TA were treated with angioplasty for symptomatic lesions or with a hemodynamically significant aortic narrowing. The patients with active disease, defined as an increase in inflammatory markers (e.g., erythrocyte sedimentation rate [ESR]), were treated with immunosuppressive agents before intervention. Angioplasty was performed after the ESR had been normalized. Results: In the 25 patients, 58 vascular territories (7 aortic, 9 carotid, 3 vertebral, 11 subclavian, 2 superior mesenteric, 18 renal, 4 iliac, and 4 coronary arteries) were treated with angioplasty only (19 lesions) or with stents (39 lesions). The mean ESR when the vascular lesions were initially diagnosed was 35.6±26.2 mm/h, which fell to 18.5±7.8 mm/h after immunosuppressive therapy. The endovascular procedure was performed successfully in 52 (90{\%}) of 58 lesions. During the mean 23.7±18.4-month follow-up, 9 (17{\%}) treated segments restenosed; 4 were treated with repeat angioplasty. The overall cumulative primary clinical success rate was 82{\%}; secondary clinical success was 90{\%}. Conclusions: Endovascular therapy for stenotic lesions in patients with TA is safe and effective when disease activity is strictly controlled with immunosuppressive treatment.",
author = "Min, {Pil Ki} and Sungha Park and Jung, {Jae Hun} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Shim, {Won Heum}",
year = "2005",
month = "2",
day = "1",
doi = "10.1583/12-01-04-1329.1",
language = "English",
volume = "12",
pages = "28--34",
journal = "Journal of Endovascular Therapy",
issn = "1526-6028",
publisher = "International Society of Endovascular Specialists",
number = "1",

}

Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with takayasu's arteritis. / Min, Pil Ki; Park, Sungha; Jung, Jae Hun; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Shim, Won Heum.

In: Journal of Endovascular Therapy, Vol. 12, No. 1, 01.02.2005, p. 28-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with takayasu's arteritis

AU - Min, Pil Ki

AU - Park, Sungha

AU - Jung, Jae Hun

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Shim, Won Heum

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Purpose: To evaluate the feasibility and efficacy of endovascular therapy combined with immunosuppression for the treatment of arterial occlusive disease in patients with Takayasu's arteritis (TA). Methods: From January 1998 to June 2003, 25 patients (22 women; age 37.8±15.5 years) with TA were treated with angioplasty for symptomatic lesions or with a hemodynamically significant aortic narrowing. The patients with active disease, defined as an increase in inflammatory markers (e.g., erythrocyte sedimentation rate [ESR]), were treated with immunosuppressive agents before intervention. Angioplasty was performed after the ESR had been normalized. Results: In the 25 patients, 58 vascular territories (7 aortic, 9 carotid, 3 vertebral, 11 subclavian, 2 superior mesenteric, 18 renal, 4 iliac, and 4 coronary arteries) were treated with angioplasty only (19 lesions) or with stents (39 lesions). The mean ESR when the vascular lesions were initially diagnosed was 35.6±26.2 mm/h, which fell to 18.5±7.8 mm/h after immunosuppressive therapy. The endovascular procedure was performed successfully in 52 (90%) of 58 lesions. During the mean 23.7±18.4-month follow-up, 9 (17%) treated segments restenosed; 4 were treated with repeat angioplasty. The overall cumulative primary clinical success rate was 82%; secondary clinical success was 90%. Conclusions: Endovascular therapy for stenotic lesions in patients with TA is safe and effective when disease activity is strictly controlled with immunosuppressive treatment.

AB - Purpose: To evaluate the feasibility and efficacy of endovascular therapy combined with immunosuppression for the treatment of arterial occlusive disease in patients with Takayasu's arteritis (TA). Methods: From January 1998 to June 2003, 25 patients (22 women; age 37.8±15.5 years) with TA were treated with angioplasty for symptomatic lesions or with a hemodynamically significant aortic narrowing. The patients with active disease, defined as an increase in inflammatory markers (e.g., erythrocyte sedimentation rate [ESR]), were treated with immunosuppressive agents before intervention. Angioplasty was performed after the ESR had been normalized. Results: In the 25 patients, 58 vascular territories (7 aortic, 9 carotid, 3 vertebral, 11 subclavian, 2 superior mesenteric, 18 renal, 4 iliac, and 4 coronary arteries) were treated with angioplasty only (19 lesions) or with stents (39 lesions). The mean ESR when the vascular lesions were initially diagnosed was 35.6±26.2 mm/h, which fell to 18.5±7.8 mm/h after immunosuppressive therapy. The endovascular procedure was performed successfully in 52 (90%) of 58 lesions. During the mean 23.7±18.4-month follow-up, 9 (17%) treated segments restenosed; 4 were treated with repeat angioplasty. The overall cumulative primary clinical success rate was 82%; secondary clinical success was 90%. Conclusions: Endovascular therapy for stenotic lesions in patients with TA is safe and effective when disease activity is strictly controlled with immunosuppressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=13644257657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13644257657&partnerID=8YFLogxK

U2 - 10.1583/12-01-04-1329.1

DO - 10.1583/12-01-04-1329.1

M3 - Article

VL - 12

SP - 28

EP - 34

JO - Journal of Endovascular Therapy

JF - Journal of Endovascular Therapy

SN - 1526-6028

IS - 1

ER -